Depression and myocardial infarction: Relationship between heart and mind

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 25, Issue 4, 2001, Pages 879-892

  Strik, J J ^a   Honig, A ^a   Maes, M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Clinical profile; Depression; Myocardial infarction risk factors; Treatment

Indexed keywords

BENZODIAZEPINE; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; PRESCRIPTION; REVIEW; RISK FACTOR; SMOKING;

EID: 0035042909     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(01)00150-6     Document Type: Article

References (73)

1. Biobehavioral variables and mortality on cardiac arrest in the Cardiac Arrhythmia pilot study (CAPS)
2. Fish consumption and risk of cardiac death
3. Mental precursors of myocardial infarction
4. Psychological prodromata of myocardial infarction and sudden death
5. Fatigue and heart disease. The association between "vital exhaustion" and past, present and future coronary heart disease
6. Dimensional structure, reliability and validity of the Dutch version of the Symptom Checklist (SCL-90)
7. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants
8. Depression and long-term mortality risk in patients with coronary heart disease
9. An inventory for measuring depression
10. Emotional support and survival after myocardial infarction. A prospective, population based study of the elderly
11. Fluoxetine in elderly patients: Is there a cause of concern?
12. Can treating depression reduce mortality after an acute myocardial infarction?
13. Insomnia and depression prior to myocardial infarction
14. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
15. Effect of the antiarrhythmic agent morizine on survival after myocardial infarction
16. Living alone after myocardial infarction: Impact on prognosis
17. Why patients do not attend cardiac rehabilitation: Role of intentions and illness beliefs
18. Personality, disease severity and the risk of long term cardiac events in patients with a decreased ejection fraction after myocardial infarction
19. Health complaints and outcome assessment in coronary heart disease
20. Personality as independent predictor of long-term mortality in patients with coronary heart disease
21. Adverse effects of type D personality and younger age on 5-year prognosis and quality of life
22. Personality and mortality after myocardial infarction
23. Enhancing recovery in coronary artery disease patients (ENRICHD): Study design and methods
24. Cardiovascular safety in depressed patients: Focus on venlafaxine
25. Gender, depression, and one-year prognosis after myocardial infarction
26. Depression following myocardial infarction: Impact on 6-months survival
27. Depression and 18 months prognosis after myocardial infarction
28. The impact of negative emotions on prognosis following myocardial infarction: Is it more than depression?
29. Randomized trial of home-based psychosocial nursing intervention for patients recovering from myocardial infarction
30. The Montreal heart attack readjustment trial
31. Underdiagnosis of depression in patients with coronary artery disease: The role of nonspecific symptoms
32. Depression following myocardial infarction
33. Depressed patients with cardiovascular disease: Treatment considerations
34. Risk of antidepressants in the elderly: Tricyclic antidepressants and Arrhythmia-Revising risks
35. Depression and the course of coronary artery disease
36. Patterns of emotional reactions after a myocardial infarction
37. Secondary prevention after acute myocardial infarction
38. International experiences with the hospital anxiety and depression rating scale: A review of validation data and clinical results
39. Depression following a first heart infarct: Similarities with and difference from "ordinary" depression
40. Psycho-immunology as a common pathway in myocardial infarction, depression and cardiac death
41. Psychological rehabilitation after myocardial infarction: Multicentre randomized controlled trial
42. The cardiac effects of therapeutic plasma concentrations of imipramine
43. Fluvoxamine: An antidepressant for the elderly?
44. Depression after a first myocardial infarction has no influence on mortality
45. Factors which provoke post-infarction depression. Results from the post-infarction late potential study
46. Post infarct depression and incomplete recovery 6 months after acute myocardial infarction
47. Affective disorders and survival after acute myocardial infarction (results from the post-infarction late potential study)
48. Major depression before and after myocardial infarction: Its nature and consequences
49. Psychological predictions of return to work after a myocardial infarction
50. Fatty acids and composition in major depression: Decreased omega-3-fractions in cholesteryl esters and increased C20:4 omega-6/C20:5 omega-3 ratio in cholesteryl esters and phospholipids
51. Cardiac rehabilitation: Socially deprived patients are less likely to attend but patients ineligible for thrombolysis are less likely to be invited
52. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: A qualitative analysis of the literature on their efficacy and side-effects
53. The relationship of depression to cardiovascular disease
54. Depression and cardiac mortality: Results from a community-based longitudinal study
55. Association between post dexamethasone cortisol levels and blood pressure in depressed inpatients
56. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia
57. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease
58. Cardiovascular effects of fluoxetine in depressed patients with heart disease
59. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease
60. Psychosocial influences on mortality after MI
61. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT trial)
62. The nature and course of depression following myocardial infarction
63. Life adjustment post-myocardial infarction: Determining predictive variables
64. Cardiac side-effects of two selective serotonin reuptake inhibitors in middle-aged and elderly depressed patients
65. Sensitivity and specificity of observer and self rating questionnaires in depression following myocardial infarction
66. Efficacy and safety of fluoxetine in the treatment of patients with major depression following first myocardial infarction: Findings from a double-blind placebo-controlled trial
67. Social and psychological responses to myocardial infarction: Multiple determinants of outcome at six months
68. Prevention of depression and anxiety in patients with cardiovascular disease
69. Treatment of depression after myocardial infarction and the effects on cardiac prognosis: The Myocardial Infarction and Depression-Intervention Trial (MIND-IT) (2000)
70. Affective, substance abuse, and anxiety disorders in persons with arthritis, diabetes, heart disease, high blood pressure or chronic lung conditions
71. Prognostic importance of somatic and psychosocial variables after a first myocardial infarction